145678-68-8

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-Methylpiperidine-3-carboxylic acid is used as a key compound for the development of antipsychotic and analgesic medications due to its potential therapeutic effects and unique chemical properties.
Used in Drug Development:
(S)-MP3CA is utilized as a promising candidate in drug development, as its structure and properties make it suitable for creating new medications with potential applications in various medical fields.
Used in Research and Development:
(S)-1-Methylpiperidine-3-carboxylic acid is employed as a subject of ongoing research to explore its pharmacological properties and determine its potential applications in the medical field, with a focus on antipsychotic and analgesic medications.

Upstream product

• 499-04-7 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid 
• 37675-18-6 (S)-(+)-nipecotic acid ethyl ester 

Relevant academic research and scientific papers

Enantioselective hydrogenation of arecaidine over cinchona alkaloid-modified palladium catalyst: A novel route to enantioenriched nipecotic acid derivatives

The hydrogenation of N-methyl-3,4-dehydronipecotic acid (arecaidine) over Pd/Al2O3 catalyst in presence of cinchona alkaloids and benzylamine additive results in the quantitative formation of N-methylnipecotic acid in good (up to 60%) optical purity. The reaction is a novel example of the efficient use of chirally modified heterogeneous metal catalysts allowing the preparation of enantioenriched N-heterocyclic carboxylic acids.

Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study

A series of potent HIV-1 protease inhibitors, containing diverse piperidine analogues as the P2-ligands, 4-substituted phenylsulfonamides as the P2'-ligands and a hydrophobic cyclopropyl group as the P1'-ligand, were designed, synthesized and evaluated in this work. Among these twenty-four target compounds, many of them exhibited excellent activity against HIV-1 protease with half maximal inhibitory concentration (IC50) values below 20 nM. Particularly, compound 22a containing a (R)-piperidine-3-carboxamide as the P2-ligand and a 4-methoxylphenylsulfonamide as the P2'-ligand exhibited the most effective inhibitory activity with an IC50 value of 3.61 nM. More importantly, 22a exhibited activity with inhibition of 42% and 26% against wild-type and Darunavir (DRV)-resistant HIV-1 variants, respectively. Additionally, the molecular docking of 22a with HIV-1 protease provided insight into the ligand-binding properties, which was of great value for further study.